Preclinical studies have suggested that CCR2 antagonists may have potential benefits in improving insulin resistance by modulating adipose tissue, as well as restoring renal function through metabolic and anti-fibrotic effects in mice with type 2 diabetes(68–69). The gene discussed is CCR2; the disease is Insulin resistance.